Abstract:
:Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat® Soft Mist™ inhaler. A total of 13 large, multicentre studies of up to 52 weeks' duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5 µg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5 µg and OLO 5 µg. TIO/OLO 5/5 µg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5 µg to TIO 5 µg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5 µg, TIO/OLO 5/5 µg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5 µg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5 µg in the management of patients with symptomatic COPD.
journal_name
Ther Adv Respir Disjournal_title
Therapeutic advances in respiratory diseaseauthors
Derom E,Brusselle GG,Joos GFdoi
10.1177/1753466619843426subject
Has Abstractpub_date
2019-01-01 00:00:00pages
1753466619843426eissn
1753-4658issn
1753-4666journal_volume
13pub_type
杂志文章,评审abstract::It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809353768
更新日期:2010-02-01 00:00:00
abstract:BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1177/1753466618778955
更新日期:2018-01-01 00:00:00
abstract::Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466620926800
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620935774
更新日期:2020-01-01 00:00:00
abstract::Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466618801167
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620953783
更新日期:2020-01-01 00:00:00
abstract::One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466619880078
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466619860058
更新日期:2019-01-01 00:00:00
abstract::Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466618760134
更新日期:2018-01-01 00:00:00
abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1177/1753465813497527
更新日期:2013-10-01 00:00:00
abstract::The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466618808660
更新日期:2018-01-01 00:00:00
abstract:OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753465813476564
更新日期:2013-08-01 00:00:00
abstract:OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,meta分析
doi:10.1177/1753465815589698
更新日期:2015-10-01 00:00:00
abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620926952
更新日期:2020-01-01 00:00:00
abstract:OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,多中心研究
doi:10.1177/1753465807086097
更新日期:2007-12-01 00:00:00
abstract::To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809103737
更新日期:2009-04-01 00:00:00
abstract::Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465812459899
更新日期:2012-12-01 00:00:00
abstract::Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753465814540029
更新日期:2014-08-01 00:00:00
abstract::Bronchiectasis occurs as a result of a vicious circle consisting of an impaired mucociliary transport system, inflammation, and infection and repair of the airways. Damage to the mucociliary system prevents secretion elimination and facilitates bacterial growth and bronchial inflammation. To facilitate mucociliary cle...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466619866102
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466618760133
更新日期:2018-01-01 00:00:00
abstract::The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465817744960
更新日期:2018-01-01 00:00:00
abstract:OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,多中心研究
doi:10.1177/1753465812438387
更新日期:2012-04-01 00:00:00
abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466620981863
更新日期:2020-01-01 00:00:00
abstract::Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753466618794133
更新日期:2018-01-01 00:00:00
abstract::Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465815579608
更新日期:2015-08-01 00:00:00
abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465810387810
更新日期:2011-02-01 00:00:00
abstract:OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,随机对照试验
doi:10.1177/1753465809350653
更新日期:2009-12-01 00:00:00
abstract::There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465813503029
更新日期:2013-12-01 00:00:00
abstract:INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章
doi:10.1177/1753466619843774
更新日期:2019-01-01 00:00:00
abstract::Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...
journal_title:Therapeutic advances in respiratory disease
pub_type: 杂志文章,评审
doi:10.1177/1753465809348014
更新日期:2009-10-01 00:00:00